Can you teach me ccf pharma drugs from basic

Reading File

Asking for Preferences

Finding Sources

Reading File

I now have comprehensive content. Let me compile the full teaching guide.

Drugs in Congestive Cardiac Failure (CCF) - Complete MBBS Guide

Source: Goldman-Cecil Medicine, Braunwald's Heart Disease

Understanding CCF First (Why We Use These Drugs)

In CCF, the failing heart activates two harmful compensatory systems:

RAAS (Renin-Angiotensin-Aldosterone System) - causes vasoconstriction, sodium retention, and cardiac remodeling
Sympathetic Nervous System - causes tachycardia, vasoconstriction, and further cardiac damage

Most CCF drugs work by blocking these two harmful systems or by relieving fluid congestion.

The 4 Pillars of HFrEF treatment (LVEF ≤ 40%) - start all as early as possible:

ARNI (or ACE-i/ARB)
Beta-blocker
MRA (mineralocorticoid receptor antagonist)
SGLT2 inhibitor

Plus diuretics for symptom relief of congestion.

DRUG CLASS 1: DIURETICS

Role

Relieve symptoms of congestion (dyspnea, edema). Do NOT improve mortality, but are needed in nearly all symptomatic patients.

Types used in CCF

Drug	Type	Mechanism	Dose
Furosemide	Loop diuretic	Blocks Na/K/2Cl cotransporter in Loop of Henle	20-80 mg/day
Chlorthalidone	Thiazide	Blocks NaCl cotransporter in distal tubule	Mild HF only
Spironolactone / Eplerenone	Potassium-sparing + MRA	Aldosterone antagonist	See MRA section

Key points

The goal is the minimum dose to maintain "dry weight" (edema-free state)
Flexible dosing: increase if edema returns, decrease if too dry
Adverse effects: hypokalemia (risk of digoxin toxicity!), hyponatremia, hyperuricemia, prerenal azotemia
NSAIDs worsen diuretic effect - avoid!
Patients should weigh daily and increase dose if weight rises >1.5-2 kg over 2 days

DRUG CLASS 2: ACE INHIBITORS (ACE-i)

Mechanism

Block the enzyme that converts Angiotensin I → Angiotensin II. This:

Reduces vasoconstriction (lowers afterload)
Prevents cardiac remodeling (myocyte hypertrophy and fibrosis)
Reduces aldosterone (less sodium retention)
Also prevents bradykinin breakdown → responsible for cough side effect

Clinical benefit

Reduces LV size, improves ejection fraction, reduces hospital admissions, prolongs survival. Recommended for ALL patients with LV systolic dysfunction (even asymptomatic, NYHA I).

Drugs and doses

Drug	Starting Dose	Target Dose
Captopril	6.25 mg TDS	50 mg TDS
Enalapril	2.5 mg BD	10-20 mg BD
Lisinopril	2.5-5 mg OD	20-35 mg OD
Ramipril	2.5 mg OD	10 mg OD

Contraindications

History of angioedema
Bilateral renal artery stenosis
Serum K+ > 5.0 mmol/L (hyperkalemia)
Systolic BP < 90 mmHg
Pregnancy

Side effects

Dry cough (due to bradykinin accumulation) - most common
Hyperkalemia
Hypotension (especially first dose)
Renal dysfunction

DRUG CLASS 3: ARBs (Angiotensin Receptor Blockers)

Mechanism

Selectively block AT1 receptor. Similar clinical effects to ACE-i, but:

Do NOT cause cough (no bradykinin accumulation)
Lower risk of angioedema

When to use

Alternative to ACE-i when ACE-i is not tolerated (e.g., cough, angioedema)
Do NOT combine ACE-i + ARB (more side effects, no benefit)

Drug	Starting Dose	Target Dose
Candesartan	4-8 mg OD	32 mg OD
Valsartan	40 mg BD	160 mg BD
Losartan	50 mg OD	150 mg OD

DRUG CLASS 4: ARNI - Sacubitril/Valsartan (Entresto) ⭐ PREFERRED FIRST LINE

Mechanism

Valsartan = ARB (blocks AT1 receptor)
Sacubitril = neprilysin inhibitor - neprilysin breaks down natriuretic peptides (ANP, BNP). By blocking neprilysin, natriuretic peptides accumulate → vasodilation, natriuresis, anti-fibrotic effects

Why it's preferred over ACE-i/ARB alone

Greater reduction in mortality and heart failure hospitalizations vs. ACE-i alone (PARADIGM-HF trial).

Important rule

Must NOT combine with ACE-i - risk of angioedema (both cause bradykinin accumulation)
Must wait 36 hours after stopping an ACE-i before starting sacubitril/valsartan

Starting dose: 24/26 mg BD → target 97/103 mg BD

DRUG CLASS 5: BETA-BLOCKERS

Why use in heart failure? (Counterintuitive but important)

The failing heart activates the sympathetic system, which initially helps but eventually causes:

Further remodeling and hypertrophy
Arrhythmias and sudden death
Receptor downregulation

Beta-blockers block this harmful chronic sympathetic activation.

Clinical benefit

Reduces mortality, hospitalizations
Improves EF and LV size over months (takes 3-6 months for full benefit)
Note: symptoms may worsen transiently when first starting - warn the patient!

Approved drugs in CCF (not all beta-blockers work - only 3 main ones)

Drug	Starting Dose	Target Dose
Bisoprolol	1.25 mg OD	10 mg OD
Carvedilol	3.125 mg BD	25-50 mg BD
Metoprolol CR/XL	12.5-25 mg OD	200 mg OD
Nebivolol	1.25 mg OD	10 mg OD (elderly)

Rule: Start LOW, go SLOW

Double dose every 2 weeks. Some beta-blocker is better than none.

Contraindications

Decompensated/acute heart failure (NYHA IV currently worsening)
Heart block (2nd/3rd degree)
HR < 60 bpm
Verapamil/diltiazem co-prescription

DRUG CLASS 6: MRA - Mineralocorticoid Receptor Antagonists

Drugs: Spironolactone, Eplerenone

Mechanism

Block aldosterone receptors → prevent sodium retention, potassium loss, and cardiac fibrosis

Clinical benefit

Increases survival, reduces hospitalizations, improves NYHA class when added to ACE-i/ARB + beta-blocker + diuretic.

Drug	Starting Dose	Target Dose
Spironolactone	25 mg OD	25-50 mg OD
Eplerenone	25 mg OD	50 mg OD

Contraindications

Serum K+ > 5.0 mmol/L
Creatinine > 221 µmol/L (>2.5 mg/dL)
Gynecomastia with spironolactone → switch to eplerenone

Monitor

K+ and creatinine at 1-2 weeks after starting (risk of hyperkalemia!)

DRUG CLASS 7: SGLT2 INHIBITORS (newest, game-changing addition)

Drugs: Dapagliflozin (Forxiga), Empagliflozin (Jardiance)

Mechanism

Block sodium-glucose cotransporter 2 in the kidney → glucosuria and natriuresis. Exact cardiac benefit mechanisms include:

Osmotic diuresis and natriuresis (reduces preload)
Improved cardiac energy metabolism
Anti-inflammatory and anti-fibrotic effects

Clinical benefit

Reduces mortality, heart failure hospitalizations, and slows decline in eGFR - even in non-diabetics!

Key point for MBBS

SGLT2 inhibitors are now first-line for HFrEF regardless of whether the patient has diabetes.

Doses

Dapagliflozin: 10 mg OD
Empagliflozin: 10 mg OD

Contraindications

eGFR < 20-25 mL/min
Previous diabetic ketoacidosis
Type 1 diabetes

DRUG CLASS 8: DIGOXIN

Mechanism

Inhibits Na+/K+-ATPase pump → increases intracellular Na+ → increases intracellular Ca2+ via Na/Ca exchanger → positive inotrope (increased contractility)

Also:

Slows heart rate (negative chronotrope) via enhanced vagal tone
Reduces sympathetic activation
Slows AV conduction (useful in AF)

Clinical benefit

Does NOT reduce mortality, but reduces hospitalizations and improves symptoms. Used as add-on when still symptomatic despite standard therapy.

When to use

Symptomatic HF despite ACE-i + beta-blocker + diuretic
HF with atrial fibrillation (slows ventricular rate) - most common indication

Dose

0.125-0.25 mg OD (renally cleared - reduce in elderly/renal impairment)

Toxicity (important exam topic!)

Narrow therapeutic index (toxic range close to therapeutic range)
Signs: nausea, vomiting, xanthopsia (yellow-green vision), arrhythmias
Hypokalemia from diuretics INCREASES digoxin toxicity risk - always check K+!
Antidote: Digoxin-specific antibody fragments (Digibind)

DRUG CLASS 9: VERICIGUAT (newer drug)

Mechanism

Soluble guanylate cyclase (sGC) stimulator → increases cGMP → vasodilation and anti-remodeling

When to use

After hospitalization for worsening HF, despite full quadruple therapy (ARNI + beta-blocker + MRA + SGLT2i)
Reduces hospitalizations but NOT mortality

Dose: 2.5 mg OD with food → double every 2 weeks → target 10 mg OD

SUMMARY TABLE: CCF Drug Pillars

Drug Class	Survival Benefit	Symptom Relief	Key Use
Diuretics (furosemide)	No	Yes	Congestion/edema
ACE-i / ARB	Yes	Yes	All HFrEF
ARNI (sacubitril/valsartan)	Yes (>ACE-i)	Yes	Preferred over ACE-i
Beta-blocker (bisoprolol, carvedilol)	Yes	Yes (long-term)	All HFrEF
MRA (spironolactone)	Yes	Yes	All HFrEF
SGLT2i (dapagliflozin)	Yes	Yes	All HFrEF (new standard)
Digoxin	No	Yes	Add-on, or AF + HF
Vericiguat	No	Yes	Worsening/refractory HF

Memory Tip for First-Line "Fantastic 4" (HFrEF)

"A Beautiful MR. Singh"

A = ARNI (Sacubitril/Valsartan)
B = Beta-blocker
MR = Mineralocorticoid Receptor antagonist
S = SGLT2 inhibitor

NYHA Classification (Know for Prescribing)

Class	Symptoms	Drug Strategy
I	No symptoms	ACE-i/ARNI if LV dysfunction found
II	Symptoms with moderate exertion	Add all 4 pillars + diuretic if needed
III	Symptoms with minimal exertion	All 4 pillars + diuretic; consider digoxin
IV	Symptoms at rest	All 4 pillars + diuretic; digoxin; specialist referral

Common MBBS Exam Questions

Q: Which diuretic is preferred in CCF? A: Furosemide (loop diuretic) - because it can be titrated and acts fast

Q: Why can't ACE-i + ARNI be combined? A: Both cause bradykinin accumulation → high risk of angioedema. Wait 36 hours between switching.

Q: Why does digoxin toxicity worsen with hypokalemia? A: Both digoxin and K+ compete for the same binding site on Na+/K+-ATPase. Low K+ means more digoxin binding = more toxicity.

Q: Which beta-blockers are approved for HF? A: Bisoprolol, Carvedilol, Metoprolol CR/XL (not atenolol, propranolol)

Q: SGLT2 inhibitors were originally developed for which disease? A: Type 2 Diabetes - but proven to benefit HF even in non-diabetics.

Q: What is the mechanism of spironolactone in CCF? A: Aldosterone receptor antagonist - prevents sodium retention, potassium loss, and cardiac fibrosis

Sources: Goldman-Cecil Medicine (9780323930345), Braunwald's Heart Disease

Can you also teach me respiratory dtugs from basic to my mbbs level like kdt

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

You've run out of free credits. Sign up for a free account to continue using Orris.

This is a shared conversation. Sign in to Orris to start your own chat.